No Data
No Data
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
Cantor Fitzgerald Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $44
Express News | Cantor Fitzgerald Initiates Coverage On Apellis Pharmaceuticals With Overweight Rating, Announces Price Target of $44
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Analysts' Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Apellis Pharmaceuticals (APLS) and Eton Pharmaceuticals (ETON)
William Blair Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating